Ann: Appendix 4C - quarterly, page-23

"The company is currently in the dose escalation phase of an open-label Phase I/II study of TLX101 called IPAX-1 across five centres in Australia and Europe. The planned recruitment for the Phase I dosing portion of the study is 22 patients, with a planned expansion to 10 more patients once the Phase II dose has been found. However, the COVID-19 pandemic has delayed the progression of the program, and the clinical study is currently paused until it can safely be resumed, which the company estimates will be possible in September or October 2020. The company is currently forecasting that initial data from the Phase I portion will be available around the end of 2020.
"https://www.edisongroup.com/publication/major-developments-coming-up/27194/

TLX101 is just a side note on there main product which is in direct competition with NOX.....ah the that is hilarious. And your here posting it as competition. Not even clear of a phase one trial and only 11 patients treated on compassionate grounds, is currently paused and only suggesting initial data at the end of 2020. But more to the point the company does not even see KZA a competition because it is not even in the same field...

"Illumet in particular may have several competitors as there are no less than three other companies developing PSMA targeted PET tracers at a similar stage of development. For comparison, we are unaware of any other companies developing CA-IX targeting PET tracers to compete with TLX250-CDx"

Far more relevant to post this on NOX for their lupin trials. But hey that would mean being relevant.